Interactions of Oxysterols with Atherosclerosis Biomarkers in Subjects with Moderate Hypercholesterolemia and Effects of a Nutraceutical Combination (


Journal

Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595

Informations de publication

Date de publication:
28 Jan 2021
Historique:
received: 21 12 2020
revised: 22 01 2021
accepted: 26 01 2021
entrez: 2 2 2021
pubmed: 3 2 2021
medline: 11 9 2021
Statut: epublish

Résumé

Oxysterol relationship with cardiovascular (CV) risk factors is poorly explored, especially in moderately hypercholesterolaemic subjects. Moreover, the impact of nutraceuticals controlling hypercholesterolaemia on plasma levels of 24-, 25- and 27-hydroxycholesterol (24-OHC, 25-OHC, 27-OHC) is unknown. Subjects ( 24-OHC and 25-OHC were significantly correlated, 24-OHC was correlated with apoB. 27-OHC and 27-OHC/total cholesterol (TC) were higher in men (median 209 ng/mL and 77 ng/mg, respectively) vs. women (median 168 ng/mL and 56 ng/mg, respectively); 27-OHC/TC was significantly correlated with abdominal circumference, visceral fat and, negatively, with high-density lipoprotein cholesterol (HDL-C). Triglycerides were significantly correlated with 24-OHC, 25-OHC and 27-OHC and with 24-OHC/TC and 25-OHC/TC. After intervention, 27-OHC levels were significantly reduced by 10.4% in the nutraceutical group Levels of 24-OHC, 24-OHC/TC, 25-OHC, 25-OHC/TC and 27-OHC/TC were unchanged. In this study, conducted in moderate hypercholesterolemic subjects, we observed novel relationships between 24-OHC, 25-OHC and 27-OHC and CV risk biomarkers. In addition, no adverse changes of OHC levels upon nutraceutical treatment were found.

Sections du résumé

BACKGROUND BACKGROUND
Oxysterol relationship with cardiovascular (CV) risk factors is poorly explored, especially in moderately hypercholesterolaemic subjects. Moreover, the impact of nutraceuticals controlling hypercholesterolaemia on plasma levels of 24-, 25- and 27-hydroxycholesterol (24-OHC, 25-OHC, 27-OHC) is unknown.
METHODS METHODS
Subjects (
RESULTS RESULTS
24-OHC and 25-OHC were significantly correlated, 24-OHC was correlated with apoB. 27-OHC and 27-OHC/total cholesterol (TC) were higher in men (median 209 ng/mL and 77 ng/mg, respectively) vs. women (median 168 ng/mL and 56 ng/mg, respectively); 27-OHC/TC was significantly correlated with abdominal circumference, visceral fat and, negatively, with high-density lipoprotein cholesterol (HDL-C). Triglycerides were significantly correlated with 24-OHC, 25-OHC and 27-OHC and with 24-OHC/TC and 25-OHC/TC. After intervention, 27-OHC levels were significantly reduced by 10.4% in the nutraceutical group Levels of 24-OHC, 24-OHC/TC, 25-OHC, 25-OHC/TC and 27-OHC/TC were unchanged.
CONCLUSIONS CONCLUSIONS
In this study, conducted in moderate hypercholesterolemic subjects, we observed novel relationships between 24-OHC, 25-OHC and 27-OHC and CV risk biomarkers. In addition, no adverse changes of OHC levels upon nutraceutical treatment were found.

Identifiants

pubmed: 33525601
pii: nu13020427
doi: 10.3390/nu13020427
pmc: PMC7911956
pii:
doi:

Substances chimiques

Biological Products 0
Biomarkers 0
Oxysterols 0
Placebos 0
red yeast rice 0
Cholesterol 97C5T2UQ7J

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Références

J Alzheimers Dis. 2013;33(4):891-911
pubmed: 23076077
Trends Pharmacol Sci. 2019 Feb;40(2):104-115
pubmed: 30665623
Biochim Biophys Acta. 1997 Feb 18;1344(3):278-85
pubmed: 9059518
Science. 2013 Nov 29;342(6162):1094-8
pubmed: 24288332
Endocrine. 2016 Dec;54(3):588-601
pubmed: 27038318
J Clin Pharmacol. 2006 Jul;46(7):812-6
pubmed: 16809807
Redox Biol. 2018 Jun;16:139-145
pubmed: 29501047
Mol Endocrinol. 2008 Jan;22(1):65-77
pubmed: 17872378
JAMA. 2009 Nov 11;302(18):1993-2000
pubmed: 19903920
Ann Med. 2016 Aug;48(5):384-91
pubmed: 27222915
Arch Neurol. 2002 Feb;59(2):213-6
pubmed: 11843691
Cell Rep. 2013 Nov 14;5(3):637-45
pubmed: 24210818
Cardiovasc Res. 2019 Jul 1;115(9):1393-1407
pubmed: 31095280
Int J Mol Sci. 2020 Jun 23;21(12):
pubmed: 32585928
Clin Cardiol. 2018 Jan;41(1):159-165
pubmed: 29363784
Clin Chim Acta. 2019 Apr;491:103-113
pubmed: 30685361
Br J Clin Pharmacol. 2015 Sep;80(3):473-9
pubmed: 26095142
Biochem Biophys Res Commun. 2014 Apr 11;446(3):692-6
pubmed: 24530911
Endocrinology. 2010 Aug;151(8):3675-85
pubmed: 20501668
Nat Rev Endocrinol. 2020 Mar;16(3):177-189
pubmed: 32020062
Hepatol Res. 2009 Feb;39(2):149-56
pubmed: 19208035
Steroids. 2012 May;77(6):575-7
pubmed: 22366074
J Clin Lipidol. 2014 Jan-Feb;8(1):61-8
pubmed: 24528686
Trends Endocrinol Metab. 2017 Jul;28(7):485-496
pubmed: 28410994
Arterioscler Thromb Vasc Biol. 2012 Sep;32(9):2045-51
pubmed: 22895665
Circ Res. 2017 Sep 1;121(6):677-694
pubmed: 28860318
Annu Rev Immunol. 2009;27:165-97
pubmed: 19302038
J Lipid Res. 1998 Dec;39(12):2477-82
pubmed: 9831637
Circulation. 2009 Oct 20;120(16):1640-5
pubmed: 19805654
Nutr Metab Cardiovasc Dis. 2012 Oct;22(10):823-30
pubmed: 21546230
Liver Res. 2019 May 21;3(2):88-98
pubmed: 32015930
Atherosclerosis. 2007 Sep;194(1):71-8
pubmed: 17107679
Nat Med. 2007 Oct;13(10):1185-92
pubmed: 17873880
Trends Endocrinol Metab. 2011 Apr;22(4):130-5
pubmed: 21353593
Clin Biochem. 2013 Oct;46(15):1619-21
pubmed: 23850851
Endocrinology. 2019 Oct 1;160(10):2485-2494
pubmed: 31386147
Eur J Hum Genet. 2019 Mar;27(3):422-431
pubmed: 30420679
Eur J Intern Med. 2015 Mar;26(2):82-8
pubmed: 25640999
Eur J Prev Cardiol. 2018 Jul;25(10):1083-1086
pubmed: 29692207
Nutr J. 2019 Feb 22;18(1):13
pubmed: 30795775
Lancet Diabetes Endocrinol. 2019 Sep;7(9):715-725
pubmed: 31301983
Eur J Intern Med. 2014 Jun;25(5):401-6
pubmed: 24685426
Eur Heart J. 2020 Jan 1;41(1):111-188
pubmed: 31504418
Atherosclerosis. 1999 Jan;142(1):1-28
pubmed: 9920502
Prog Lipid Res. 2016 Oct;64:152-169
pubmed: 27687912
Am J Pathol. 2002 Feb;160(2):701-10
pubmed: 11839591
Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7238-43
pubmed: 10377398
J Biol Chem. 2014 Jan 10;289(2):747-64
pubmed: 24280213
Biochimie. 2018 Oct;153:3-12
pubmed: 29751082
Eur J Nutr. 2018 Mar;57(2):499-511
pubmed: 27757595
Cardiovasc Ther. 2008 Winter;26(4):297-316
pubmed: 19035881
J Clin Lipidol. 2015 Mar-Apr;9(2):226-33
pubmed: 25911079
Genes Dev. 2000 Nov 15;14(22):2831-8
pubmed: 11090131
Cytotechnology. 2017 Jun;69(3):485-492
pubmed: 26983933

Auteurs

Stefania Cicolari (S)

Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, 20133 Milan, Italy.

Chiara Pavanello (C)

Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, 20133 Milan, Italy.
Centro E. Grossi Paoletti, Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, 20133 Milan, Italy.

Elena Olmastroni (E)

Servizio di Epidemiologia e Farmacologia Preventiva (SEFAP), Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, 20133 Milan, Italy.

Marina Del Puppo (MD)

Dipartimento di Medicina e Chirurgia, Università degli Studi di Milano Bicocca, 20900 Monza, Italy.

Marco Bertolotti (M)

Dipartimento di Scienze Biomediche, Metaboliche e Neuroscienze, Università degli Studi di Modena e Reggio Emilia, 41126 Modena, Italy.

Giuliana Mombelli (G)

Centro Dislipidemie, ASST Grande Ospedale Metropolitano Niguarda, 20162 Milan, Italy.

Alberico L Catapano (AL)

Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, 20133 Milan, Italy.
IRCCS MultiMedica, Sesto S. Giovanni, 20099 Milan, Italy.

Laura Calabresi (L)

Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, 20133 Milan, Italy.
Centro E. Grossi Paoletti, Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, 20133 Milan, Italy.

Paolo Magni (P)

Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, 20133 Milan, Italy.
IRCCS MultiMedica, Sesto S. Giovanni, 20099 Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH